Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 4 Date: 18 Mar 2022
Reviewer's report:
The authors constructed a novel evaluation with stool DNA and fecal immunochemical test(FIT)
for early colorectal cancer (CRC) detection and treatment of CRC.
The study included 14 patients with CRC and 345 patients from the screening population.
Patients had one of the following inclusion criteria: (1) Previous positive history of FOBT;
(2) Family history of colorectal cancer; and (3) Chronic intestinal disease such as diarrhea,
constipation, mucinous bloody stool, appendicitis, and biliary tract disease. Therefore most of
these patients had the indication to directly undergo endoscopy without second-line screening
stool test.
To evaluate the accuracy of the new screening test, a comparison with fist-line FOBT should
be performed.
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 4 Date: 18 Mar 2022
Reviewer's report:
The authors constructed a novel evaluation with stool DNA and fecal immunochemical test(FIT)
for early colorectal cancer (CRC) detection and treatment of CRC.
The study included 14 patients with CRC and 345 patients from the screening population.
Patients had one of the following inclusion criteria: (1) Previous positive history of FOBT;
(2) Family history of colorectal cancer; and (3) Chronic intestinal disease such as diarrhea,
constipation, mucinous bloody stool, appendicitis, and biliary tract disease. Therefore most of
these patients had the indication to directly undergo endoscopy without second-line screening
stool test.
To evaluate the accuracy of the new screening test, a comparison with fist-line FOBT should
be performed.
Please review this paper.
user
Title: Feasibility of quantification based on novel evaluation with stool DNA and fecal
immunochemical test for colorectal cancer detection
Version: 4 Date: 18 Mar 2022
Reviewer's report:
The authors constructed a novel evaluation with stool DNA and fecal immunochemical test(FIT)
for early colorectal cancer (CRC) detection and treatment of CRC.
The study included 14 patients with CRC and 345 patients from the screening population.
Patients had one of the following inclusion criteria: (1) Previous positive history of FOBT;
(2) Family history of colorectal cancer; and (3) Chronic intestinal disease such as diarrhea,
constipation, mucinous bloody stool, appendicitis, and biliary tract disease. Therefore most of
these patients had the indication to directly undergo endoscopy without second-line screening
stool test.
To evaluate the accuracy of the new screening test, a comparison with fist-line FOBT should
be performed.
assistant